Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Pain, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Bone Diseases, Metabolic, Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Ductal, Breast

Breast Neoplasms

Breast Neoplasms, Osteoporosis

Breast Neoplasms, Neovascularization, Pathologic

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Multiple Myeloma, Pain, Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms, Pain

Breast Neoplasms, Osteoporosis

Breast Neoplasms, Osteoporosis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Micrometastasis

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms, Multiple Myeloma

Breast Neoplasms

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Clinical Trials

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

REaCT-ZOL

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

ANZAC

HOBOE

Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole

Study on Bisphosphonates Targeting Triple-negative Breast Cancer

BLAZE

REaCT-BTA

Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NEOZOL

Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Pre-operative Zoledronate in Triple Negative Breast Cancer

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

ER11-03

Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer

Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

NATAN

CTIBL

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

esozao

Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer

Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole

Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation

Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients